Publication date: October 23, 2025
KIEŁTYKA GŁADKOWSKI KG LEGAL participated in the conference “Longevity Biotech: Investing in a healthier future”. As part of its life science specialisation, our biotech and pharma lawyers offer comprehensive legal services to its clients in many areas of law, including extensive legal services to companies operating in the longevity biotech sector and biotech companies engaged in life extension and human health. Within this specialism our law firm offers assistance in respect of trademark protection and patent issues, regulatory law, certification, contractual, and litigation and arbitration issues. At KG Legal, we know that a key role in the biotechnology sector is innovation and responsiveness to changing market needs. Therefore, we offer our clients a proactive approach, flexibility and efficiency in action. All these qualities of our firm make us recognized as one of the leading law firms in Poland and the world, especially in the field of cross-border specialization and knowledge.
Longevity biotech investing in a healthier future
The theme of the conference was “Longevity biotech investing in a healthier future”. The conference is designed to introduce investors to the longevity biotech industry – Focused on delivering clinically transformative products that solve the most challenging aspects of today’s medicine, and to help navigate the rapidly changing investment landscape in this field. The conference discussed defining longevity biotech, the opportunities, risks and business models associated with investing in companies in this industry.
Biotech Start-ups: Innovative Solutions for Medicine, Agriculture and Industry.
Biotechnology companies, also known as biotech start-ups, are companies that are engaged in scientific research, the manufacture and distribution of biological products and the application of biological technologies, molecular biology in various fields such as medicine, agriculture, industry and environmental protection. These companies apply the latest advances in science and technology to develop innovative solutions that have a positive impact on the quality of human and animal life. The focus of biotechnology companies is primarily the study and use of biomolecules, such as proteins, enzymes, nucleic acids or polysaccharides. Their goal is to develop new methods of diagnosing diseases and therapies based on biomolecules, as well as to provide solutions for the growing healthcare market.
It is important to mention that biotech companies play a key role in today’s world, as their innovative approaches to medicine can revolutionize the way diseases are treated. Through molecular research and the development of new drugs, these companies are striving to find solutions to diseases that were previously incurable or required lengthy and expensive treatment. The biotechnology sector is one of the fastest-growing sectors of the economy, with an estimated market value of hundreds of billions of dollars. Such companies focus on researching and developing innovative solutions for the elderly and finding ways to improve the quality of life for seniors. Examples include anti-cancer, anti-viral, anti-inflammatory drugs, as well as research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Using the latest biotechnology methods, these companies are researching medications, dietary supplements, functional foods, cosmetics, biodegradable materials, biofuels, as well as laboratory research and consulting services.
Biotechnology companies are popular with investors because of their huge growth opportunities and prospects for high profits. It is expected that in the next few years the value of the biotech market will continue to grow, and with it the number of biotech companies and investors. First, many of these companies have strong growth potential, which means that an investment in them can yield high returns. Second, many are engaged in innovative projects that can have a positive impact on human health and the environment, which attracts investors with social interests. Third, biotech companies are often backed by governments and nonprofit organizations that invest in scientific research and technological innovation, which contributes to the value of these companies.
Longevity biotech companies in Poland and around the world
Longevity biotech is biotechnology sector that focuses on developing therapies, medications and medical products that aim to extend the length and quality of human life. Longevity biotech companies are engaged in molecular, genetic and pharmaceutical research to develop new drugs and therapies that can help treat diseases associated with the aging process. Examples of longevity biotech companies include:
What legal issues do longevity biotech companies face?
Longevity biotech companies engaged in research and development of therapies and drugs face a number of legal issues, both in Poland and internationally. Here are some of those issues:
Intellectual property protection – Longevity biotech companies typically invest heavily in research and development of new drugs and therapies. To protect their investments, they must pay attention to protecting their intellectual property rights, such as patents, trademarks and industrial secrets.
Regulatory compliance – Research and development of new drugs and therapies usually requires clinical trials and regulatory approvals.
Ethical requirements – In developing new drugs and therapies, longevity biotech companies must comply with ethical and moral requirements. In some cases, this may mean that certain studies or tests are not allowed or must be carried out with great care.
Product liability – The longevity biotech companies are responsible for the safety of their products and therapies. In the event of any illegal or ethical activities, these companies can be charged with product liability violations.
Funding – Longevity biotech companies often need large amounts of funding for research and development. As a result, they need to seek investors and pay attention to various financing issues, such as restrictive loan terms or stock issues.
Patent law: Biotechnology companies, including longevity biotechs, can apply for patents on their discoveries and inventions. Many of these patents relate to discoveries in genetics, gene therapy and other scientific fields, which can lead to litigation and legal challenges.
Copyright: Biotechnology companies often work with software and other information technologies that may be protected by copyright. If these rights are violated, companies may have to pay damages or be subject to criminal prosecution.
Right to privacy: The operations of longevity biotech companies may require the use of patient data and other medical information. As such, the companies must comply with privacy laws, including data protection laws.
Patient consents: Many biotechnology studies require the use of human samples and medical data. To do so, companies must obtain patients’ consents to use their data and samples.
Market regulations: Biotechnology companies must comply with strict market regulations, such as product registration requirements, certification and approval procedures, as well as quality standards.
Legal regulations for biotech companies in Poland: What do you need to know before starting your own company?
In Poland, longevity biotech companies are regulated by a number of different laws that can affect their operations, such as the Pharmaceutical Law and the Medical Devices Act regulate the pharmaceutical market in Poland and set requirements for clinical trials, registration and distribution of drugs and medical devices. Longevity biotech companies must comply with these regulations when developing new therapies and medications.
Patent Law – The Industrial Property Law regulates the protection of intellectual property in Poland, including patents for inventions and plant varieties. Longevity biotech companies must obtain relevant patents for their research, therapies and drugs.
Personal Data Protection Act – The Personal Data Protection Act of May 10, 2018 regulates the processing of personal data, including patient data, by longevity biotech companies. It requires companies to comply with relevant rules for processing and protecting personal data. These regulations introduce a number of obligations for the processing of personal data by companies, including biotech companies. For these companies, due to the nature of their business, the personal data processed is often particularly sensitive and legally protected. Biotech companies may process the personal data of their employees, contractors, as well as patients participating in clinical trials, for example, as part of the process of bringing new drugs to market. The processing of this data must be carried out in accordance with the provisions of GDPR, which means, among other things, that consent must be obtained to process the data, that it must be secured against unauthorized access, and that the rights of data subjects can be realized. In the event of a violation of GDPR, biotechnology companies may be liable for fines, as well as negative image and reputational consequences.